A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)

Inclusion Criteria: * Men and Women age 50-90 * Alzheimer's disease diagnosis with at least 6-month decline in cognitive function * Non-childbearing potential or using adequate birth control * Mini-Mental State Exam (MMSE) 15-28 * Available/consenting Study Partner * Able to identify a Legally Authorized Representative (LAR) * Stable chronic conditions at least 30 days * Formal education of 8 or more years * Adequate vision (Able to detect light) and hearing * Mobility sufficient for compliance with testing procedures (ambulatory or aided-ambulatory, i.e. cane or walker) * Amyloid or phosphorylated Tau positivity Exclusion Criteria: * Seizure disorder * Hospitalization in previous 30 days * Living in continuous care nursing home (assisted living permitted) * Inability to have an MRI or significant abnormality on MRI screening * Geriatric Depression Scale (GDS) \>6 * Suicidality (current or previous 6 months) * Serious neurological diseases affecting the Central Nervous System, including: 1. other primary degenerative dementias (Lewy-body dementia, fronto-temporal dementia, Huntington's disease, Creutzfeldt-Jakob disease, Down syndrome, mixed dementia, etc), 2. neurodegenerative conditions (Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, etc), 3. serious infection of the brain (meningitis/encephalitis), or 4. history of multiple concussions. * Metabolic or systemic diseases affecting the central nervous system (syphilis, B12 or folate deficiency, etc) * Schizophrenia or bipolar disorder * Heart disease, chronic liver, kidney, or respiratory disease, or uncontrolled diabetes or thyroid disease * Cancer history within previous 2 years (except resolved non-melanoma skin or stable prostate) * Nootropic drugs except stable acetylcholinesterase inhibitors * Drug or Alcohol abuse in previous 12 months * Previous exposure to Anti-amyloid-beta vaccines * Past Exposure to Immunomodulators or passive immunotherapies for AD (ie, monoclonal antibodies) * Exposure to BACE (β-Site amyloid precursor protein cleaving enzyme) inhibitors within the 6 months prior to consent * Involved in a previous Cognito study or gamma therapy study * Active treatment with Memantine (Namenda or Namzaric) within previous 30 days * Life expectancy \< 24 months Participants involved in the Fluid Biomarker substudy also must not have contraindications to lumbar puncture. For more information visit: https://www.hopestudyforad.com/